Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 10,556 matching trials from the live ClinicalTrials.gov search.

Filters: Cincinnati, Ohio Clear all

Conditions: Fanconi Anemia
Interventions: Etanercept; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 4 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more

Conditions: Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma, T-cell Leukemia, Recurrent Disease, Acute Leukemia
Interventions: Palbociclib, Cytarabine, Methotrexate, Hydrocortisone, Doxorubicin, Prednisolone, Vincristine, Pegaspargase, Prednisone; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 31 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 19
States / cities: Birmingham, Alabama • Loma Linda, California • Orange, California + 15 more

Conditions: Down Syndrome, Fetal Aneuploidy
Interventions: Not listed
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 3,062 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 27
States / cities: Mobile, Alabama • Tucson, Arizona • Campbell, California + 24 more

Conditions: Aortic Coarctation
Interventions: Treatment of Aortic Wall Injury; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 19
States / cities: San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 16 more

Conditions: Small Cell Lung Carcinoma
Interventions: Ipilimumab, Placebo matching Ipilimumab, Etoposide, Cisplatin, Carboplatin; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 42
States / cities: Hot Springs, Arkansas • Auburn, California • La Jolla, California + 34 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 12 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 48
States / cities: Downey, California • Long Beach, California • Los Angeles, California + 28 more

Conditions: Urolithiasis, Stones, Kidney, Renal Stones, Kidney Stones
Interventions: CVAC® SYSTEM, FLEXIBLE AND NAVIGATIONAL URETERAL ACCESS SHEATH (FANS) IN FLEXIBLE URETEROSCOPY (FURS), DIRECT IN-SCOPE SUCTION (DISS) IN FLEXIBLE URETEROSCOPY (FURS), URETEROSCOPY (URS) WITHOUT SUCTION, PERCUTANEOUS NEPHROLITHOTOMY (PCNL); Device · Procedure
Lead sponsor: Calyxo, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Miami, Florida • Wichita, Kansas • Cheektowaga, New York + 6 more

Conditions: Primary Open-angle Glaucoma and Ocular Hypertension
Interventions: DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 13
States / cities: Los Angeles, California • Danbury, Connecticut • Brooksville, Florida + 10 more

Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions: Ambrisentan, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 51
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Davis, California + 40 more

Conditions: Hodgkin Disease
Interventions: Nivolumab, brentuximab vedotin, bendamustine; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 5 Years to 30 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 40 more

Conditions: Obesity, Overweight
Interventions: LY3305677, LY3841136, Tirzepatide, LY3549492, LY3532226, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 49
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 44 more

Conditions: Idiopathic Parkinson's Disease
Interventions: Istradefylline 40 mg, Istradefylline 20 mg, Placebo; Drug
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 30 Years and older
Enrollment: 613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 41
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 36 more

Conditions: Bipolar Depression
Interventions: aripiprazole; Drug
Lead sponsor: Lindner Center of HOPE; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Paroxysmal Supraventricular Tachycardia
Interventions: Etripamil NS; Drug
Lead sponsor: Milestone Pharmaceuticals Inc.; Other
Eligibility: 6 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Phoenix, Arizona • Oak Lawn, Illinois • Cincinnati, Ohio + 3 more

Conditions: Peripheral Vascular Disease
Interventions: Not listed
Lead sponsor: Hansen Medical; Industry
Eligibility: 18 Years and older
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Los Angeles, California • Miami, Florida • Cincinnati, Ohio + 2 more

Conditions: Hypertension
Interventions: diet high in fruits, vegetables, and dairy, Routine nutrition care; Behavioral · Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 11 Years to 18 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Uterine Fibroids, Heavy Menstrual Bleeding
Interventions: Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 92
States / cities: Birmingham, Alabama • Mobile, Alabama • Costa Mesa, California + 79 more

Conditions: Esophagitis
Interventions: Ilaprazole, Lansoprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 94
States / cities: Hueytown, Alabama • Huntsville, Alabama • Chandler, Arizona + 91 more

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: topotecan hydrochloride; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Up to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more

Conditions: Acute Myeloid Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 6 Months to 21 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 186
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more

Conditions: Carcinoma, Small Cell
Interventions: Topotecan, carboplatin; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 16
States / cities: Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 13 more

Conditions: Pompe Disease (Late-Onset), Glycogen Storage Disease Type II (GSD-II), Glycogenesis Type II, Acid Maltase Deficiency (AMD)
Interventions: alglucosidase alfa; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 8 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 26
States / cities: Anchorage, Alaska • Phoenix, Arizona • Beverly Hills, California + 23 more

Conditions: Meningitis, Meningococcal Infection, Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Serotype b (Hib)
Interventions: Meningococcal polysaccharide diphtheria toxoid conjugate, Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 9 Months to 18 Months
Enrollment: 1,394 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 56
States / cities: Birmingham, Alabama • Pinson, Alabama • Tucson, Arizona + 50 more

Search by objective public record fields.

Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies

Covered CP Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

The Safety of Different Dose Levels of Zidovudine in HIV-Infected Children

Stone Clearance With Aspiration vs Other Technologies: a Real-world Evidence Study

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression

The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)

Registry of the Magellan Robotic System

A Nutrition Intervention to Lower Blood Pressure in Adolescents

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis

Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Late-Onset Treatment Study Extension Protocol

Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age